Trenton, February 5, 2026 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey (HINJ – www.hinj.org), released the following statement concerning the federal government’s newly-announced direct-purchase program for prescription medicines:
“Many biopharma companies have long offered direct-purchase programs to help patients when middlemen and insurers make it difficult to access medicines. These companies continue to introduce new options that have the potential to save patients and employers money while increasing access to prescriptions.”
Buteas continued, “There are right ways to lower prices and wrong ways. A ‘most favored nation’ government-imposed price control would decimate new cures, hand America’s innovation leadership over to China, and reduce patient access – all without actually lowering prices. But direct-purchase programs, coupled with the PBM reforms enacted by Congress earlier this week, will continue to help patients access the life-saving medicines New Jersey companies work so hard to research, discover and manufacture.”
Buteas concluded, “We will continue our partnership with all stakeholders, from individual patients to the White House, to find even more ways to lower healthcare costs for all Americans without jeopardizing American innovation and future cures.”